NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS

(19)

(11)

EP 3 104 847 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	30.12.2020 Bulletin 2020/53

(45)	Mention of the grant of the patent:
	11.11.2020 Bulletin 2020/46

(21)	Application number: 15715809.8

(22)	Date of filing: 09.02.2015

(51)

International Patent Classification (IPC):

A61K 31/135^(2006.01)
A61K 31/15^(2006.01)
A61P 11/00^(2006.01)

A61K 31/138^(2006.01)
A61P 9/10^(2006.01)
A61P 21/00^(2006.01)

(86)	International application number:
	PCT/HU2015/000014

(87)	International publication number:
	WO 2015/118365 (13.08.2015 Gazette 2015/32)

(54)	NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS NEUARTIGE VERWENDUNG VON SIGMA-1-REZEPTORAGONISTENVERBINDUNGEN NOUVELLE UTILISATION DE COMPOSÉS AGONISTES DU RÉCEPTEUR SIGMA-1

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

07.02.2014 EP 14462004

(43)	Date of publication of application:
	21.12.2016 Bulletin 2016/51

(73)	Proprietors:
	Támogatott Kutatócsoportok Irodája 1051 Budapest (HU) Semmelweis Egyetem 1085 Budapest (HU)

(72)	Inventors:
	FEKETE, Andrea H-1013 Budapest (HU) VANNAY, Ádám H-1147 Budapest (HU)

(74)	Representative: Svingor, Adam
	Danubia Patent & Law Office LLC POB 198 1368 Budapest 1368 Budapest (HU)

(56)

References cited: :

WO-A1-2013/103317

HIDEAKI TAGASHIRA: "Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist", YAKUGAKU ZASSHI : JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 132, no. 2, 1 February 2012 (2012-02-01), pages 167-172, XP055132767,
KENJI HASHIMOTO: "Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression", PROGRESS IN NEUROBIOLOGY, vol. 100, 1 January 2013 (2013-01-01), pages 15-29, XP055132954, ISSN: 0301-0082, DOI: 10.1016/j.pneurobio.2012.09.001
XUE-QIN LI ET AL: "Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats", ACTA PHARMACOLOGICA SINICA, vol. 32, no. 2, 10 January 2011 (2011-01-10), pages 217-222, XP055153193, ISSN: 1671-4083, DOI: 10.1038/aps.2010.187
GAYRAUD ET AL: "Raynaud's phenomenon", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 74, no. 1, 14 February 2007 (2007-02-14), pages e1-e8, XP005891813, ISSN: 1297-319X, DOI: 10.1016/J.JBSPIN.2006.07.002

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).